SCHEMBL19994496

SCHEMBL19994496

CCOC(=O)c1ccc2nc(-c3ccc([N+](=O)[O-])cc3)[nH]c2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 6/20 0.72
SIRT1 Q96EB6 5/20 0.72
SIRT3 Q9NTG7 2/20 0.72
PKN1 Q16512 1/20 0.71
PKN2 Q16513 1/20 0.71
CHEK2 O96017 3/20 0.66
NPBWR1 P48145 5/20 0.65
MMP2 P08253 3/20 0.64
MMP9 P14780 3/20 0.64
MMP8 P22894 3/20 0.64
MMP13 P45452 3/20 0.64
NPC1 O15118 2/20 0.62
MAPT P10636 2/20 0.62
HTT P42858 2/20 0.62
RAB9A P51151 2/20 0.62
CASP3 P42574 1/20 0.62
SENP8 Q96LD8 1/20 0.62
SENP7 Q9BQF6 1/20 0.62
SENP6 Q9GZR1 1/20 0.62
MEN1 O00255 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19995192 0.88 NPBWR1 (0.69) CHEK2NPBWR1MMP2MMP9MMP8
SCHEMBL27651947 0.87 NPBWR1 (0.59) SIRT2SIRT1SIRT3PKN1PKN2
SCHEMBL20982711 0.85 SIRT2 (0.64) SIRT2SIRT1SIRT3PKN1PKN2
SCHEMBL19994531 0.84 SIRT2 (0.79) SIRT2SIRT1SIRT3PKN1PKN2
SCHEMBL19994427 0.83 PKN1 (1.00) SIRT2SIRT1SIRT3PKN1PKN2
SCHEMBL27002575 0.83 PKN1 (1.00) SIRT2SIRT1SIRT3PKN1PKN2
SCHEMBL5217725 0.83 CHEK2 (0.87) CHEK2NPBWR1MMP2MMP9MMP8
SCHEMBL27002550 0.82 CHEK2 (0.87) PKN1PKN2CHEK2NPBWR1MMP2
SCHEMBL19994503 0.82 CHEK2 (0.87) PKN1PKN2CHEK2NPBWR1MMP2
SCHEMBL5219206 0.81 NPBWR1 (0.77) PKN1PKN2CHEK2NPBWR1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509465-B2 Benzoimidazole derivatives as anticancer agents CENTRE LEON BERARD (FR) 2025-12-30 US disclosed
EP-3515904-B1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS CENTRE LEON BERARD (FR) 2024-01-17 EP disclosed
CN-110234640-B Benzimidazole derivatives as anticancer agents 利昂贝拉尔中心 2023-04-07 CN disclosed
US-20220348587-A1 Benzoimidazole Derivatives As Anticancer Agents CENTRE LEON BERARD (FR) 2022-11-03 US disclosed
US-11384081-B2 Benzoimidazole derivatives as anticancer agents CENTRE LEON BERARD (FR) 2022-07-12 US disclosed
US-20210292328-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS CENTRE LEON BERARD (FR) 2021-09-23 US disclosed
EP-3515904-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS Centre Leon Berard (FR) 2019-07-31 EP disclosed
WO-2018054989-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS CENTRE LEON BERARD (FR) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509465-B2 Benzoimidazole derivatives as anticancer agents CCAR2, MAPKAP1, BCOR SIRT2 1935/4885SIRT1 2148/4885SIRT3 1770/4885
US-20210292328-A1 BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS TMBIM6, BAX, MAPK14 SIRT2 1954/4885SIRT1 2241/4885SIRT3 1988/4885
US-11384081-B2 Benzoimidazole derivatives as anticancer agents TMBIM6, BAX, MAPK14 SIRT2 1954/4885SIRT1 2241/4885SIRT3 1988/4885
US-20220348587-A1 Benzoimidazole Derivatives As Anticancer Agents TMBIM6, BAX, BCL2 SIRT2 1990/4885SIRT1 2253/4885SIRT3 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.